What is Implanet?
Founded in 2007, IMPLANET is a medical technology company dedicated to manufacturing high-quality implants for orthopedic surgery. The company's product portfolio includes the JAZZ® and OSD systems for spinal pathologies and the MADISON implant for knee surgery. IMPLANET's orthopedic platform is distinguished by its product traceability and is protected by international patents. Its flagship JAZZ® system has achieved regulatory clearance from the FDA in the United States, the CE mark in Europe, and ANVISA approval in Brazil, positioning it as a key player in the global orthopedic market. The company employs 29 staff and reported sales of 6.0 million in 2020.
How much funding has Implanet raised?
Implanet has raised a total of $2.1M across 1 funding round:
Debt
$2.1M
Debt (2024): $2.1M with participation from SPD Silicon Valley Bank
Key Investors in Implanet
SPD Silicon Valley Bank
SPD Silicon Valley Bank is a joint venture focused on serving the technology and innovation industry, providing unique financial products and services to companies in sectors including life science and biotechnology. Their mission is to increase client success by fostering an innovation ecosystem.
What's next for Implanet?
The recent major strategic investment in Implanet signals a pivotal moment for the company, likely enabling accelerated research and development, expansion into new markets, and enhancement of its manufacturing capabilities. With regulatory approvals already secured in key global regions, this capital infusion is expected to bolster its commercialization efforts and solidify its competitive position in the orthopedic implant sector. The company's focus on innovative solutions for spinal and knee conditions, coupled with its established product traceability, positions it for sustained growth and increased market share.
See full Implanet company page
